GlassScriptPhysician profile
Karen K Hoffmann
NPI 1629072426
$222,567.14
in general payments reported to CMS, 2019-2025
34 companies · $15K in 2025
The $15K reported for 2025 was more than what 98% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $44K · 2021: $78K · 2022: $40K · 2023: $17K · 2024: $2,120 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,400 · Travel and Lodging: $4,842 · Food and Beverage: $4,458 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,287.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,400.00 |
| Travel and Lodging | $4,841.87 |
| Food and Beverage | $4,457.91 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $116,989.40 | 2019-2023 | |
| Acclarent, INC | $84,855.10 | 2019-2024 | Trudi Nav Cable, Acclarent Aera |
| Medtronic, INC. | $9,451.47 | 2024-2025 | Hydrodebrider, Propel, Sinuva |
| Aerin Medical INC. | $3,672.67 | 2019-2025 | |
| Integra Lifesciences Corporation | $3,660.51 | 2024-2025 | Integra, Acclarent Aera, Integra Dermal Regeneration Template |
| Regeneron Healthcare Solutions, INC. | $661.95 | 2019-2025 | Dupixent |
| Biosense Webster, INC. | $638.40 | 2019 | |
| Spirair, INC. | $423.27 | 2025 | |
| Genzyme Corporation | $311.05 | 2019-2025 | |
| Glaxosmithkline, LLC. | $276.66 | 2021-2025 | Nucala |
| Optinose US, INC. | $251.15 | 2019-2025 | |
| Intersect Ent, INC. | $218.33 | 2019-2022 | |
| Neurent Medical Limited | $151.38 | 2022-2023 | Neuromark Device, Neuromark Radiofrequency Console |
| Stryker Corporation | $139.33 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $134.55 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $103.33 | 2022-2024 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $100.97 | 2025 | Neffy |
| Kaleo, INC. | $95.52 | 2019-2023 | Auvi-Q |
| Amgen INC. | $83.33 | 2020-2025 | Tezspire |
| Acelrx Pharmaceuticals, INC. | $47.09 | 2021-2022 | |
| Alk-Abello, INC | $43.02 | 2022 | |
| Cochlear Americas | $35.91 | 2024 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Abbvie INC. | $30.60 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.37 | 2024 | Cuvitru |
| Merck Sharp & Dohme LLC | $21.10 | 2023 | |
| Medtronic USA, INC. | $20.43 | 2020 | |
| Novartis Pharmaceuticals Corporation | $18.05 | 2019 | |
| Smith+Nephew, INC. | $16.81 | 2024 | Ent Sinus |
| Depuy Synthes Sales INC. | $16.58 | 2020 | |
| 3nt Medical | $16.50 | 2023 | |
| Phadia US INC. | $15.13 | 2021 | |
| Aytu Biopharma, INC. | $15.03 | 2021 | |
| Olympus America INC. | $14.22 | 2019 | |
| Karl Storz Endoscopy-America | $13.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.